Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S Announces Filing Of IND Application With FDA To Start Phase I Dose Escalation Trial Of HuMax-TF-ADC To Treat Multiple Solid Tumors


Thursday, 18 Jul 2013 10:30am EDT 

Genmab A/S announced the filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start a Phase I dose escalation trial of HuMax-TF-ADC to treat multiple solid tumors. A maximum of 78 patients with cancer of the ovary, cervix, endometrium, bladder, prostate, head & neck, esophagus or lung that have failed or are not eligible for standard treatments will be enrolled in the study. The safety and tolerability of HuMax-TF-ADC will be established during a dose escalation part of the study. This will be followed by a cohort expansion part that will investigate longer-term safety and potential signs of anti-tumor activity. 

Company Quote

226.3
-3.5 -1.52%
29 Aug 2014